Puntuación CHA₂DS₂-VASc
Escrito por Equipo de informática para pacientesPublicado originalmente 8 Feb 2026
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
Profesionales Médicos
Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar uno de nuestros artículos de salud más útil.
The CHA₂DS₂-VASc score is a clinical risk stratification tool used to estimate the risk of stroke and systemic embolism in patients with fibrilación auricular (FA). It is widely used to guide decisions about oral anticoagulation.
The score refines earlier risk models by including additional vascular and demographic risk factors and is recommended in UK and international guidelines.
Contexto clínico y uso
CHA₂DS₂-VASc is used in patients with non-valvular atrial fibrillation, including paroxysmal, persistent, and permanent AF.
Its primary purpose is to identify patients who are likely to benefit from anticoagulation in order to reduce the risk of ischaemic stroke. It is typically used alongside bleeding risk assessment and shared decision-making.
The score should be recalculated periodically, as stroke risk increases with age and the development of new comorbidities.
Components of the CHA₂DS₂-VASc score
Points are assigned for the following risk factors:
Congestive heart failure or left ventricular dysfunction: 1 point.
Hipertensión, treated or untreated: 1 point.
Age 75 years or older: 2 points.
Diabetes mellitus: 1 point.
Prior accidente cerebrovascular, ataque isquémico transitorio, o systemic embolism: 2 points.
Vascular disease, including previous infarto de miocardio, peripheral arterial disease, or aortic plaque: 1 point.
Age 65–74 years: 1 point.
Sex category female: 1 point.
The total score ranges from 0 to 9.
Interpretation of scores
Higher scores indicate a greater annual risk of stroke.
In UK practice, anticoagulation is generally recommended for:
Men with a score of 2 or more.
Women with a score of 3 or more.
Anticoagulation may be considered for:
Men with a score of 1.
Women with a score of 2.
A score of 0 in men, or 1 in women where the only point is sex category, is generally considered low risk and does not usually require anticoagulation.
Decisions should always be individualised and made in the context of patient preference, bleeding risk, and overall clinical picture.
Role in anticoagulation decisions
The CHA₂DS₂-VASc score helps identify patients who are likely to derive net benefit from anticoagulation therapy.
It does not determine the choice of anticoagulant. Selection between direct oral anticoagulants and vitamin K antagonists depends on patient characteristics, contraindications, renal function, drug interactions, and local guidance.
Stroke prevention strategies should be reviewed regularly, particularly after hospital admissions or changes in health status.
Base de evidencia
CHA₂DS₂-VASc has been validated in large cohort studies and has demonstrated improved discrimination of stroke risk compared with earlier scoring systems.
It is incorporated into NICE, ESC, and other international guidelines for the management of atrial fibrillation.
Limitaciones y juicio clínico
The score estimates population-level risk and does not predict individual outcomes with certainty.
It does not account for bleeding risk, frailty, or life expectancy, which must also be considered. Bleeding risk assessment tools, such as HAS-BLED, are commonly used alongside CHA₂DS₂-VASc to support balanced decision-making.
The score should not be used in patients with mechanical heart valves or moderate to severe mitral stenosis, where anticoagulation decisions follow different guidance.
Uso práctico en consulta
Using a recognised scoring system can support consistent prescribing, documentation, and audit. Recording the score also helps structure discussions with patients about stroke risk and the potential benefits and risks of anticoagulation.
Actualizaciones exclusivas para profesionales de la salud
Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Historial del artículo
Artículo también disponible en Inglés, Alemán, Español, Francés, Italiano, Portugués, Hindi, Hebreo, Árabe, y Sueco.
8 Feb 2026 | Publicado originalmente
Escrito por:
Equipo de informática del paciente
Más sobre enfermedades cardiovasculares
- Defecto del tabique auricular
- La enfermedad de Buerger
- Investigaciones cardíacas
- Injerto de derivación de la arteria coronaria
- Epidemiología de la enfermedad coronaria
- Prueba de tolerancia al ejercicio
- Hematoma extradural
- Hipertensión en el embarazo
- Cardiomiopatía hipertrófica
- Inserción de marcapasos temporales
- Trombosis venosa intracraneal
- Enfermedad de Kawasaki
- Endocarditis eosinofílica de Löffler
- Síndrome de Lown-Ganong-Levine
- Prolapso de la válvula mitral
- Prevención de la endocarditis infecciosa
- Embolia pulmonar
- Enfermedad de la válvula pulmonar
- Aneurisma aórtico roto
- Fibrilación ventricular


